|
February 4, 2010
|
| 07:55 EDT |  | ITMN |
| theflyonthewall.com: | InterMune risk/reward not attractive into upcoming events, says Jefferies | | Jefferies believes the risk/reward profile on InterMune shares is not attractive into the FDA Committee panel for pirfenidone scheduled for March 9, 2010. The firm expects a mixed panel outcome and reiterates an Underperform rating on the stock. :theflyonthewall.com |
|
|
February 3, 2010
|
| 09:53 EDT |  | ITMN |
|
|
February 2, 2010
|
| 09:48 EDT |  | ITMN |
|
|
February 1, 2010
|
| 13:17 EDT | | ITMN |
|
| 10:06 EDT |  | ITMN |
| theflyonthewall.com: | InterMune says FDA committee to discuss drug on March 9, 2010 | | InterMune announced that the FDA's Pulmonary-Allergy Drugs Advisory Committee is scheduled to discuss the company's New Drug Application for pirfenidone on March 9, 2010. Pirfenidone is InterMune's investigational drug candidate for the treatment of patients with idiopathic pulmonary fibrosis. :theflyonthewall.com |
|
| 09:51 EDT | | ITMN |
|
| 09:44 EDT | | ITMN |
| theflyonthewall.com: | Active equity option families in first 10-minutes | | Active equity option families in first 10-minutes of trading according to Track Data are: C ITMN AAPL JPM. :theflyonthewall.com |
|
|
January 28, 2010
|
| 05:33 EDT | | ITMN |
| theflyonthewall.com: | Warburg Pincus increases stake in Intermune to 17.7% from 15.8% | | :theflyonthewall.com |
|
Subscribe for More Information